Integral Diagnostics 将来の成長

Future 基準チェック /46

Integral Diagnostics利益と収益がそれぞれ年間31.3%と9.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に9.3% 31.1%なると予測されています。

主要情報

31.3%

収益成長率

31.15%

EPS成長率

Healthcare 収益成長	18.8%
収益成長率	9.7%
将来の株主資本利益率	9.30%
アナリストカバレッジ	Good
最終更新日	21 Nov 2025

今後の成長に関する最新情報

Recent updates

Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success

Apr 27 Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.

Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

Feb 28

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17

業績と収益の成長予測

ASX:IDX - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2028	907	69	77	148	8
6/30/2027	854	58	68	135	10
6/30/2026	805	48	68	120	10
6/30/2025	627	5	14	74	N/A
3/31/2025	559	5	24	73	N/A
12/31/2024	491	6	34	73	N/A
9/30/2024	481	-28	38	70	N/A
6/30/2024	470	-61	42	66	N/A
3/31/2024	463	-59	29	62	N/A
12/31/2023	456	-58	16	58	N/A
9/30/2023	449	-16	20	63	N/A
6/30/2023	441	25	23	67	N/A
3/31/2023	418	23	20	56	N/A
12/31/2022	395	21	17	45	N/A
9/30/2022	378	18	13	41	N/A
6/30/2022	361	15	9	37	N/A
3/31/2022	361	18	14	41	N/A
12/31/2021	360	22	18	44	N/A
9/30/2021	356	26	34	57	N/A
6/30/2021	351	31	49	70	N/A
3/31/2021	333	32	54	73	N/A
12/31/2020	315	32	59	76	N/A
9/30/2020	295	28	44	65	N/A
6/30/2020	276	23	28	54	N/A
3/31/2020	263	22	19	47	N/A
12/31/2019	250	21	9	39	N/A
9/30/2019	241	21	12	37	N/A
6/30/2019	232	21	15	34	N/A
3/31/2019	222	19	N/A	30	N/A
12/31/2018	211	17	N/A	26	N/A
9/30/2018	200	16	N/A	26	N/A
6/30/2018	189	15	N/A	27	N/A
3/31/2018	187	15	N/A	27	N/A
12/31/2017	185	15	N/A	27	N/A
9/30/2017	182	15	N/A	25	N/A
6/30/2017	180	15	N/A	23	N/A
3/31/2017	177	16	N/A	26	N/A
12/31/2016	175	16	N/A	30	N/A
9/30/2016	171	14	N/A	27	N/A
6/30/2016	168	11	N/A	24	N/A
3/31/2016	165	11	N/A	22	N/A
12/31/2015	162	11	N/A	20	N/A
9/30/2015	157	8	N/A	18	N/A
6/30/2015	151	5	N/A	17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: IDXの予測収益成長率 (年間31.3% ) は貯蓄率 ( 3.3% ) を上回っています。

収益対市場: IDXの収益 ( 31.3% ) はAustralian市場 ( 12% ) よりも速いペースで成長すると予測されています。

高成長収益: IDXの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: IDXの収益 ( 9.7% ) Australian市場 ( 5.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: IDXの収益 ( 9.7% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: IDXの自己資本利益率は、3年後には低くなると予測されています ( 9.3 %)。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/11/25 22:10
終値	2025/11/25 00:00
収益	2025/06/30
年間収益	2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Integral Diagnostics Limited 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。19

アナリスト	機関
Benjamin Brayshaw	Barrenjoey Markets Pty Limited
Thomas Yeo	Barrenjoey Markets Pty Limited
Saul Hadassin	Barrenjoey Markets Pty Limited

Integral Diagnostics 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Price target increased by 7.1% to AU$3.34

Consensus EPS estimates fall by 14%

Price target decreased by 7.3% to AU$3.15

Price target increased by 7.7% to AU$2.93

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 11%

Recent updates

New major risk - Dividend sustainability

Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025

Final dividend increased to AU$0.04

Price target increased by 7.1% to AU$3.34

Full year 2025 earnings released: EPS: AU$0.016 (vs AU$0.26 loss in FY 2024)

Consensus EPS estimates fall by 14%

New minor risk - Dividend sustainability

Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success

Private Equity Players Reportedly Keep Close Tabs on Integral Diagnostics

Independent Non-Executive Chairman recently bought AU$79k worth of stock

Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

First half dividend of announced

Price target decreased by 7.3% to AU$3.15

First half 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive Director

Integral Diagnostics Limited Announces Company Secretary Changes

New major risk - Shareholder dilution

High number of new directors

Integral Diagnostics Limited Announces Board Appointments

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).

Integral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Price target increased by 7.7% to AU$2.93

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings: EPS misses analyst expectations

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Consensus EPS estimates fall by 12%

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Consensus EPS estimates fall by 11%

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings: EPS misses analyst expectations

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Consensus EPS estimates fall by 16%

Integral Diagnostics Limited Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued after recent price drop

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Independent Non-Executive Director recently bought AU$114k worth of stock

Consensus forecasts updated

Now 22% undervalued after recent price drop

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to AU$3.65

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Now 21% undervalued after recent price drop

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Now 21% undervalued

Executive Director recently bought AU$70k worth of stock

Consensus forecasts updated

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate